Zylox-tonbridge Medical Technology Co., Ltd. Class H · HKEX:2190
Zylox-tonbridge Medical Technology Co., Ltd. Class H — FY2023 Earnings Presentation
36 slides from Zylox-tonbridge Medical Technology Co., Ltd. Class H's earnings presentation, April 2024
Slide 1: Zylox-Tonbridge 2023 Annual Results Presentation
Zylox-Tonbridge（2190.HK） 2023 Annual Results Presentation April 2024
Slide 2: Disclaimer
Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase
Slide 3: Business Highlights
Business Highlights Financial Sales R&D Acting strategically in the Volume-based Procurements 528 million RMB Number of NMPA Revenue • Quickly expanded our hospital access for the 16 registration approvals + 58.0% YOY Growth products by capturing the bid-winning obtained in 2023 opportunities of the
Slide 4: Financial Highlights
Financial Highlights • High revenue growth, the trend of profits emerged
Slide 5: Commercialization of High-quality Products Triggered Rapid Revenue Growth
Commercialization of High-quality Products Triggered Rapid Revenue Growth Rapid Revenue Growth from 2021 Overseas Revenue from 2021H1 （ in 000’ RMB） （ in 000’ RMB） Gross Profit 74.1% 75.6% 72.9% Margin： 527,754 14,272 2021-2023 CAGR：72% 144,653 2021-2023 CAGR：103% 334,090 7,796 100,692 177,912 381,7
Slide 6: Neurovascular - Rapid Revenue Growth
Neurovascular - Rapid Revenue Growth Revenue of Neurovascular Products Main Source of Revenue （ in 000’ RMB） % of Revenue : 63.1% 69.9% 72.3% Thrombite SilverSnake Clot Retriever Intracranial Device Support Catheter 381,799 64% Phoenix Baiju Detachable Coil Intracranial System Balloon Catheter 233,3
Slide 7: Peripheral-vascular - Steady Revenue Growth
Peripheral-vascular - Steady Revenue Growth Revenue of Peripheral-vascular Products Main Source of Revenue （ in 000’ RMB） % of Revenue : 36.9% 30.1% 27.4% Drug Coated High Pressure PTA Balloon PTA Balloon Catheter Catheter 144,653 44% PTA Balloon Endovenous Catheter Radiofrequency Ablation (RFA) 100
Slide 8: Increased Operational Efficiency in Line with Business Development
Increased Operational Efficiency in Line with Business Development Selling and Distribution Expenses R&D Expenses Administrative Expenses % of Revenue % of Revenue % of Revenue 95% 70% 57% 54% 50% 42% 31% 33% 22% 2021A 2022A 2023A 2021A 2022A 2023A 2021A 2022A 2023A Amount 95,269 140,137 163,827 168
Slide 9: Trend of Profits Emerged with Improved Sales Scale and Efficiency
With the Continuous Improvement of Sales Scale and Operational Efficiency, the Trend of Profits Emerged Other Non-operating Income and Expenses Adjusted Net Profit / (Loss ) 3 （ in 000’ RMB） （ in 000’ RMB） 2021A 2022A 2023A 2021A 2022A 2023A 140,000 30,000 7,033 120,000 0 10,802 100,000 11,066 -30,0
Slide 10: Sufficient Cash and Efficient Operations to Support Rapid Growth
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years 2023 Cash Status Trade Receivables Turnover Trade Payables Turnover （ in 000’ RMB） （ Turnover Days ） （ Turnover Days ） 2,693,107 2,577,065 73 55 48 91,482 540 0.6 0.8 0.8 (4,504) (203,056) 2021A 2022A 2023A 2021A 20
Slide 11: Sales and Marketing
Sales and Marketing • Extensive Sales Network and Rapid Commercialization Progress
Slide 12: Deeply Cultivate the Domestic Market and Build an Extensive Sales Network
Deeply Cultivate the Domestic Market and Build an Extensive Sales Network Steady Expansion of the Sales Marketing Team Supports the Rapid Development Rapid commercialization capabilities Numbers of Provincial Procurement Platforms that Newly Launched Products are Included into in Last One Year Numbe
Slide 13: Continuing to Strengthen the Channel Advantage to Build a Mature Dealer System
Continuing to Strengthen the Channel Advantage to Build a Mature Dealer System Distributors Across the Country 2024 National Channel Development Forum Number of Secondary Distributors Nationwide 449 337 221 2021 2022 2023 The company's comprehensive product portfolio promotes overall sales promoti
Slide 14: Commercialization of key products
Commercialization of key products SilverSnake Intracranial Support Catheter Thrombite Clot Retriever Device Baiju Intracranial Balloon Catheter Phoenix Detachable Coil System Launched in Sept. 2020 Launched in Sept. 2020 Launched in Mar. 2021 Launched in Sept. 2021 Market share of approximately 20%
Slide 15: Continued to Grow International Business and Further Enhanced our Brand Awareness
Continued to Grow International Business and Further Enhanced our Brand Awareness Products Approved in Overseas Markets Product Approved Region Neurovasc Thrombite Clot Retriever Device CE and 6 countries including Germany, UK, South Africa, etc. ular Aspiration Catheter CE and 6 countries includi
Slide 16: Embraced VBPs and increased products' market penetration
Leveraging a differentiated and comprehensive product portfolio, Embraced VBPs and increased products’ market penetration Beijing-Tianjin-Hebei “3+N” Alliance VBP Clot Retriever Device I and Clot Retriever Device ll won the bid, with Clot Retriever Device II securing the first place in Group B；
Slide 17: Neurovascular Portfolio – Industry leader in advocating Trans-radial Approach
Neurovascular Interventional Portfolio – Industry leader in advocating the Concept and Technique of Trans-radial Approach (TRA) Oct. 2023 Radial Access Distal Support Catheter Launched ahead of schedule May 2023 • Held meetings and training sessions to provide physicians with opportunities of simula
Slide 18: Neurovascular Portfolio – Professional Academic Marketing Strategy
Neurovascular Interventional Portfolio – Professional Academic Marketing Strategy Doctor training support activities： • Conducting BADDASS training courses in 8 sites in 2023, including Beijing, Shanghai, Guangzhou, Shaanxi, Gansu, Fujian, Hunan and Liaoning; • Organized BADDASS case competitions in
Slide 19: Peripheral Vascular Portfolio – Professional Academic Marketing Strategy
Peripheral Vascular Interventional Portfolio – Professional Academic Marketing Strategy A Variety of Activities Promiting One-stop Solution for VTE ( Venous Thromboembolism ) Domestic Leading One-stop VTE solution Provider Guiding Hundreds of Domestic Hospitals to Enhance the Concept of Venous Vascu
Slide 20: Peripheral-vascular Interventional Portfolio – Professional Academic Marketing Strategy
Peripheral-vascular Interventional Portfolio – Professional Academic Marketing Strategy Zylox Institute Widely Engaged Healthcare Professionals Domestic Virtual Meetings to Exchange Surgical Skills Active Participation in Professional Academic Conferences CCI 2022 VINNOVA2023 SJVF 2023 CAVS 2023 为患者
Slide 21: R&D
21 R&D • Advance R&D with great efficiency steadily and innovatively
Slide 22: Rich and Comprehensive Product Portfolio to Meet Huge Clinical Demand
Rich and Comprehensive Product Portfolio to Meet Huge Clinical Demand Intracranial Ischemic Stroke Peripheral Artery Disease Procedure Volume： 110,000 units（2023） Procedure Volume： 170,000 units（2023） BADDASS ： Clot Retriever Device + Support Catheter + BGC PTA Balloon（Normal 、High Pressure） + DCB +
Slide 23: Neurovascular Interventional Portfolio — 28 Products
Neurovascular Interventional Portfolio—— 28 Products 9 Products 19 Approved Products （4 Approved） 2020 2021-2022 2023 2024 2025 2026 2 Approved 9 Approved 8 Approved 4 Products（4 Approved） 2 Products 3 Products Intracranial Ischemic Stroke Thrombite Clot Microcatheter Retriever Device Balloon Guidin
Slide 24: Key Product to be Launched: Flow Diverter
Key Product to be Lunched in Neurovascular Interventional Portfolio —— Flow Diverter Market Opportunities (1) and Competitive Landscape Product Features Intracranial aneurysm interventional flow-directed device • Through-body visualization ： implantation procedure volume in China( 2015-2030E ) Nit
Slide 25: Key Product to be Launched: Self-expandable Intracranial Stent
Key Product to be Lunched in Neurovascular Interventional Portfolio —— Self-expandable Intracranial Stent Market Opportunities (1) and Competitive Landscape Product Features Volume of intracranial aneurysm embolisation-assisted stenting procedures in China ( 2015-2030E ) Auxiliary embolic stent de
Slide 26: Peripheral-Vascular Interventional and Vascular Closure Devices Portfolio — 35 Products
Peripheral-Vascular Interventional and Vascular Closure Devices Portfolio—— 35 Products 17 Approved Products 18 Products（3 Approved） 2024 2026 2027 2020 2021-2022 2023 2025 4 Products 5 1 4 Approved 4 Approved 9 Approved 8 Products （3 Approved） Products Products Peripheral Drug Eluting Stent System
Slide 27: Key Product to be Launched: Peripheral Venous Stent System
Key Product to be Lunched From Peripheral-vascular Interventional Portfolio —— Peripheral Venous Stent System Market Opportunities (1) Product Features Number of patients with iliac vein compression syndrome • Vein-specific design (IVCS) in China( 2015-2030E ) Laser engraved one-piece molding, mor
Slide 28: Key Product to be Launched: IVL System
Key Product to be Lunched From Peripheral-vascular Interventional Portfolio —— IVL System • 冲击波球囊 Product Structure Product Features Circuit design with independent IP rights Submit nearly 10 invention patent applications , 3 of Generator them granted. Intelligent Energy Control System Connector
Slide 29: Key Product to be Launched: Avinger Lumivascular Portfolio
Key Product to be Lunched From Peripheral Vascular Interventional Portfolio—— Avinger Lumivascular product portfolio Avinger Lumivascular product portfolio Portfolio Resolution Radically improved console Lumivascular Stenosis Peripheral with enhanced high-definition Platform Hydrophilic Pathway OC
Slide 30: Prospects
Prospects 30
Slide 31: Building on our industry leadership in 2024
Building on our industry leadership in 2024 Optimize product portfolio Continued expansion of product and accelerate innovation market share based on solid based on clinical needs commercialization capabilities • Optimize product portfolio by exploring • Provide the market with differentiated clinic
Slide 32: Appendix
Appendix Please refer to 2023 Annual Results Announcement for further information Click to download
Slide 33: Financial Reports
Y TERMED ZYLOX-TONBRIDGE Financial Reports
Slide 34: Consolidated Statements of Profit or Loss
Consolidated Statements of Profit or Loss Year ended December 31 RMB’000 2021 % of Revenue 2022 % of Revenue 2023 % of Revenue Revenue 177,912 100% 334,090 100% 527,754 100% Cost of sales -46,031 -26% -81,421 -24% -142,766 -27% Gross Profit 131,881 74% 252,669 76% 384,988 73% Selling and distributio
Slide 35: Consolidated Balance Sheet
Consolidated Balance Sheet As at RMB’000 31-Dec-2021 31-Dec-2022 31-Dec-2023 Non-current assets Property, plant and equipment 178,270 290,243 538,540 Right-of-use assets 34,115 48,136 39,820 Intangible assets 4,889 9,637 9,686 Prepayments and other receivables 6,804 10,645 4,278 Financial assets at
Slide 36: Consolidated Balance Sheet
Consolidated Balance Sheet As at 31-Dec-2021 31-Dec-2022 31-Dec-2023 RMB’000 Non-current liabilities 0 0 8,674 Deferred revenue 6,509 7,459 1,859 Lease liabilities 6,509 7,459 10,533 Total non-current liabilities Trade and other payables 86,307 126,652 233,886 Contract liabilities 3,420 9,601 19,922
Zylox-Tonbridge Medical Technology — FY2023 Earnings Presentation on 6ix